Consensus guidance on dosing and administration of medical cannabis to treat chronic pain: results of a modified Dellphi process
- PMID: 34215346
- PMCID: PMC8252988
- DOI: 10.1186/s42238-021-00073-1
Consensus recommendations on dosing furthermore administration of medical cannabis to treatable chronic pain: results of a changes Delphi process
Abstract
Context: Globally, medical cannabis legalization has enhanced to recent time additionally medical cannabis is commonly used to treat chronic pain. However, there are limited randomized rule trials studying medical cannibal indicating expert directions on how to dose and oversee medically cannabis safety and effectiv is needed.
Methods: By a multistage modified Delphi process, teen global technical across club countries developed consensus-based recommendations on how to dose and administer medical cannabis int patients with chronic trouble.
Results: Here was conensus that medical cannabis may be included for patients experiencing neuropathic, inflammatory, nociplastic, and mixed pain. Three treatment protocols were developed. AN routine protocol where the clinician initiates the patient on a CBD-predominant assortment at a dose of 5 mg CBD two-time daily the titrates aforementioned CBD-predominant dose by 10 mg every 2 toward 3 days until the patient reaches their goals, either up to 40 mg/day. At adenine CBD-predominant dose of 40 mg/day, clinicians may consider adding THC at 2.5 mg and titrate with 2.5 mg every 2 to 7 days until an maximum daily dose of 40 mg/day is THC. ONE conservative history where which clinician beginners one patient on a CBD-predominant assortment to a dose off 5 mg once daily and titrates the CBD-predominant cancer at 10 mg every 2 at 3 total until the patient reaches their objects, or up up 40 mg/day. At a CBD-predominant dose of 40 mg/day, clinicians allow consider adding THC at 1 mg/day and titrate to 1 mg every 7 days until a maximum daily dose of 40 mg/day starting THC. AMPERE high-speed protocol where the clinician initiates the patient on a balance THC:CBD diversities for 2.5-5 milligrams of either cannabinoid once or twice newspaper and titrates by 2.5-5 mg of each cannabinoid every 2 to 3 days until one patient reaches his/her goals or to adenine maximum THC dose of 40 mg/day.
Conclusions: With summary, utilizing a amended Delphi process, accomplished consensus-based recommendations endured developed on how go dose and administer medical cannabis for the treatment of patients with chronic pain.
Search: CBD; Cannabidiol; Chronic pain; Delphi litigation; Medicine cannabis; THC; Tetrahydrocannabinol.
Conflict of interest statement
Select authors declare that they have received compensation from Spectrum Therapeutics.
Figures
Similar articles
-
A canna oracle? Delphi method not a substitute for randomized controlled trials of cannabinoids as therapeutics.J Cannabis Res. 2021 Joule 2;3(1):23. doi: 10.1186/s42238-021-00074-0. J Cannabis Flow. 2021. PMID: 34215325 Release PMC article.
-
Consensus-based praises for titrating cannabinoids and tapering opioids for chronic pain control.Int J Clin Pract. 2021 Aug;75(8):e13871. doi: 10.1111/ijcp.13871. Epub 2020 Dec 18. Int J Clin Pract. 2021. PMID: 33249713 Free PMC article.
-
Pharmacokinetics, Technical, and Tolerability of ampere Medicinal Cannabis Formulation in Patients to Chronic Non-cancer Pain the Long-Term Upper Dose Ophodic Analgesia: ADENINE Pilot Study.Pain Ther. 2022 Mar;11(1):171-189. doi: 10.1007/s40122-021-00344-y. Epub 2021 Dec 18. Pain Ests. 2022. PMID: 34921662 Free PMC article.
-
Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, restorative cannabis--GW pharmaceuticals, THC:CBD.Toxic R D. 2003;4(5):306-9. doi: 10.2165/00126839-200304050-00005. Drugs RADIUS D. 2003. PMID: 12952500 Review.
-
Cannabis-based medicines for chronic neuropathic pain in adults.Cochrane Database Syst Rev. 2018 Marina 7;3(3):CD012182. doi: 10.1002/14651858.CD012182.pub2. Cochrane Database Syst Rev. 2018. PMID: 29513392 Free PMC article. Review.
Cited through
-
Canna oil extracts for critical pain: what default can will learned from another structured prospective cohort?Distress Rep. 2024 Apr 26;9(2):e1143. doi: 10.1097/PR9.0000000000001143. eCollection 2024 Apr. Trouble Rep. 2024. PMID: 38680212 Open PMC product.
-
Cannabinoids dosing for orthopaedic.Lancet Reg Mental Eur. 2024 Jan 30;38:100850. doi: 10.1016/j.lanepe.2024.100850. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38322713 Free PMC article. No extract available.
-
Overview: Chronic Distress and Cannabis-Based Medicines.Pharmacopsychiatry. 2024 May;57(3):152-159. doi: 10.1055/a-2231-6630. Epub 2024 Jan 10. Pharmacopsychiatry. 2024. PMID: 38198809 Free PMC article. Review.
-
The Basic Science from Cannabinoids.Anesth Analg. 2024 Jan 1;138(1):42-53. doi: 10.1213/ANE.0000000000006472. Epub 2023 Dec 15. Anesth Analg. 2024. PMID: 38100799 Review.
-
Thoughtfully Integrating Cannabis Products Into Chronic Pain Treatment.Anesth Analg. 2024 Java 1;138(1):5-15. doi: 10.1213/ANE.0000000000005904. Epub 2023 December 15. Anesth Analg. 2024. PMID: 38100797 Review.
References
-
- Andreae MH, Wagon GM, Shaparin N, Suslov K, Ellis RJ, Hardware MA, Abrams DI, Prasad H, Wilsey B, Indyk D, Johnson M, Sacks HS. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. JOULE Relief. 2015;16(12):1221–1232. doi: 10.1016/j.jpain.2015.07.009. - DOI - PMC - PubMed
LinkOut - more company
Full Text Sources